Active surveillance is widely used for men with low-risk prostate cancer, but existing tools have important limitations and monitoring relies on repeated biopsies that burden patients and practices.
MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of the NeXT Dx™ Test to help oncologists identify potential ...
FREMONT, Calif. & CHICAGO--(BUSINESS WIRE)--Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc., a leader in artificial intelligence and ...
Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration (“FDA”) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be ...
Changes in bone mineral density with adjuvant aromatase inhibitor treatment and breast cancer recurrence. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does not ...
Diagnostics manufacturer Abbott recently announced FDA clearance of the Afinion HbA1c Dx assay for use with the Afinion™ AS100 Analyzer. The assay is the first-ever rapid point-of-care test approved ...
Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results